Addressing comorbidity in adults with attention-deficit/hyperactivity disorder

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 7, 1998, Pages 69-75

  Hornig, Mady ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; CANNABIS; COCAINE; DESIPRAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NADOLOL; NICOTINE; NORADRENALIN; PROPRANOLOL; PSYCHOSTIMULANT AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AFFECTIVE NEUROSIS; ANTISOCIAL BEHAVIOR; ANXIETY NEUROSIS; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DRUG EFFICACY; GILLES DE LA TOURETTE SYNDROME; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; NEUROCHEMISTRY; OBSESSION; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SUBSTANCE ABUSE; SYMPTOMATOLOGY; TRANSDERMAL DRUG ADMINISTRATION;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BUPROPION; CHILD; CLINICAL TRIALS; COMORBIDITY; CYCLOHEXANOLS; DOPAMINE; DOPAMINE ANTAGONISTS; EPINEPHRINE; HUMANS; MENTAL DISORDERS; NOREPINEPHRINE; PREVALENCE; PSYCHOTROPIC DRUGS; SEROTONIN;

EID: 0031818255     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Wender P. Attention deficit hyperactivity disorder in adults: a wide view of a widespread condition. Psychiatr Ann 1997;27:556-562
2. Wender PH. Attention Deficit Hyperactivity Disorder in Adults. New York, NY: Oxford University Press; 1995
3. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409-432
4. Halperin JM, Healey JM, Are ADDH and ADHD the same or different? J Am Acad Child Adolesc Psychiatry 1989;285:734-738
5. Shekim WO, Asarnow RF, Hess E, et al. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder residual state. Compr Psychiatry 1990;31:416-425
6. Wender PH, Reimherr FW, Wood D, et al. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 1985;142:547-552
7. Huessy HR, Metoyer M, Townsend M. Eight to ten year follow-up of 84 children treated for behavioral disturbance in rural Vermont. Acta Paedopsychiatrica 1974;40:230-235
8. Mendelson W, Johnson N, Stewart MA. Hyperactive children as adolescents: a follow-up study. J Nerv Ment Dis 1971;153:273-279
9. Wood DR, Reimherr FW, Wender PH, et al. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry 1976;33:1453-1460
10. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methyphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52: 434-443
11. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry 1996;37: 393-401
12. Hallowell EM, Ratey JJ. Driven to Distraction. New York, NY: Pantheon Books; 1994
13. First MB, Gibbon M, Spitzer RL, et al. Structured Clinical Interview for DSM-IV Axis I Disorders. New York, NY: Biometric Research, New York State Psychiatric Institute; 1996
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association; 1994
15. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993;150:1792-1798
16. Biederman J, Faraone S, Milberger S, et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1996;35:343-351
17. Biederman J, Faraone S, Mick E, et al. Psychiatric comorbidity among referred juveniles with major depression: fact or artifact? J Am Acad Child Adolesc Psychiatry 1995;34:579-590
18. Milberger S, Biederman J, Faraone SV, et al. Attention deficit hyperactivity disorder and comorbid disorders: issues of overlapping symptoms. Am J Psychiatry 1995;152:1793-1799
19. Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorders in adults. Clin Neuropharmacol 1985;8:343-356
20. Mattes J, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry 1984;41: 1059-1063
21. Wender PH, Reimherr FW, Wood DR. Attention deficit disorder ("minimal brain dysfunction") in adults: a replication study of diagnosis and drug treatment. Arch Gen Psychiatry 1981;38:449-456
22. Greenhill LL. Attention deficit hyperactivity disorder: the stimulants. Child Adol Psychiatr Clin North Am 1995;4:123-168
23. Physicians' Desk Reference, 51st edition. Oradell, NJ: Medical Economics; 1997
24. Heinonen EH, Anttila MI, Karnani HL, et al. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. J Clin Pharmacol 1997;37:602-609
25. Gelowitz DL, Richardson JS, Wishart TB, et al. Chronic L-deprenyl or L-amphetamine: equal cognitive enhancement, unequal MAO inhibition. Pharmacol Biochem Behav 1994;47:41-45
26. Ernst M, Liebenauer LL, Jons PH, et al. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety. Psychopharmacol Bull 1996;32:327-334
27. Feigin A, Kurlan R, McDermott MP, et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology 1996;46:965-968
28. Jankovic J. Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol 1993;50:286-288
29. Parran TV, Jasinski DR. Intravenous methylphenidate abuse: prototype for prescription drug abuse. Arch Intern Med 1991;151:781-783
30. Zametkin AJ, Rapoport JL. Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years? J Am Acad Child Adolesc Psychiatry 1987;26:676-686
31. Irwin M, Belendiuk K, McCloskey K, et al. Tryptophan metabolism in children with attentional deficit disorder. Am J Psychiatry 1981;138: 1082-1085
32. Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol Psychiatry 1992;32:1-17
33. Schultz W. Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol 1997;7:191-197
34. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science 1997;275:1593-1599
35. Fibiger HC, Phillips AG. Mesocorticolimbic dopamine systems and reward. Ann N Y Acad Sci 1988;537:206-215
36. Brown GL, Ebert MH, Goyer PF, et al. Aggression, suicide, and serotonin: relationships to CSF amine metabolites. Am J Psychiatry 1982;139: 741-746
37. Charney DS, Nagy LM, Bremner JD, et al. Neurobiological mechanisms of human anxiety. In: Fogel BS, Schiffer RB, Rao SM, eds. Neuropsychiatry. Baltimore, Md: Williams & Wilkins; 1996:257-286
38. Hunt RD. Nosology, neurobiology, and clinical patterns of ADHD in adults. Psychiatric Annals 1997;27:572-581
39. Milberger S, Biederman J, Faraone SV, et al. Attention deficit hyperactivity disorder and comorbid disorders: issues of overlapping symptoms. Am J Psychiatry 1995;152:1793-1799
40. Alpert JE, Maddocks A, Nierenberg AA, et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res 1996;62:213-219
41. Ratey JJ, Greenberg MS, Bemporad JR, et al. Unrecognized attention-deficit hyperactivity disorder in adults presenting for outpatient psychotherapy. J Child Adolesc Psychopharmacol 1992;2:267-275
42. Hornig-Rohan M, Amsterdam JD. Venlafaxine vs stimulant therapy in patients with dual diagnoses of attention deficit disorder and depression. Psychopharmacol Bull 1995;31:580
43. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996;153:1147-1153
44. Rapaport MD, Carlson CA, Kelly KL, et al. Methylphenidate and desipramine in hospitalized children, I: separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 1993;32:333-342
45. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. New York, NY: Oxford University Press; 1991
46. Sarter M, Bruno JP. Trans-synaptic stimulation of cortical acetylcholme and enhancement of attentional functions: a rational approach for the development of cognition enhancers. Behav Brain Res 1997; 83:7-14
47. Robbins TW. Arousal systems and attentional processes. Biol Psychol 1997;45:57-71
48. Klein DF. Endogenomorphic depression: a conceptual and terminological revision. Arch Gen Psychiatry 1974;31:447-454
49. Wozniak J, Biederman J, Kiely K, et al. Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry 1995;34:867-876
50. Wozniak J, Biederman J, Mundy E, et al. A pilot family study of childhood-onset mania. J Am Acad Child Adolesc Psychiatry 1995;34:1577-1583
51. Faraone S, Biederman J, Milberger S. How reliable are maternal reports of their children's psychopathology? One year recall of psychiatric diagnoses of ADHD children. J Am Acad Child Adolesc Psychiatry 1995;34: 1001-1008
52. Sachs GS, Baldassano CF, Truman CJ, et al. Comorbidity of ADHD with early- and late-onset bipolar disorder. In: New Research Program and Abstracts of the 149th Annual Meeting of the American Psychiatric Association: May 8, 1996; New York, N.Y. Abstract NR646:246
53. Diehl DJ, Gershon S. The role of dopamine in mood disorders. Compr Psychiatry 1992;33:115-120
54. Ascher JA, Cole JO, Colin J-N, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401
55. Wender PH, Reimherr FW. Bupropion treatment of attention deficit disorder in adults. Am J Psychiatry 1990;147:1018-1020
56. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-393
57. Zarate CA Jr, Tohen M, Baraibar G, et al. Prescribing trends of antidepressants in bipolar depression. J Clin Psychiatry. 1995;56:260-264
58. Fogelson DL, Bystritsky A, Pasnau R. Bupropion in the treatment of bipolar disorders: the same old story? J Clin Psychiatry 1992;53:443-446
59. Stoll AL, Mayer PV, Kolbrener M, et al. Antidepressant-associated mania: a controlled comparison with spontaneous mania. Am J Psychiatry 1994; 151:1642-1645
60. Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-1081
61. Montgomery SA. Venlafaxine: a new dimension in antidepressant pharmacotherapy [ACADEMIC HIGHLIGHTS]. J Clin Psychiatry 1993;54:119-126
62. Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996;57:184-189
63. Adler LA, Resnick S, Kunz M, et al. Open label trial of venlafaxine (Effexor) in attention deficit disorder. Psychopharmacol Bull 1995;31: 785-788
64. Reimherr FW, Hedges DW, Strong RE, et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull 1995;31:609
65. Wilens TE, Biederman J, Spencer TJ. Venlafaxine for adult ADHD [letter]. Am J Psychiatry 1995;152:1099-1100
66. Biederman J; Wilens T; Mick E, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995;152: 1652-1658
67. Manshadi M, Lippmann S, O'Daniel RG, et al. Alcohol abuse and attention deficit disorder. J Clin Psychiatry 1983;44:379-380
68. Wilens TE, Biederman J, Spencer TJ, et al. Comorbidity of attention deficit hyperactivity disorder and the psychoactive substance use disorders. Hospital and Community Psychiatry 1994;45:421-435
69. Hechtman L, Weiss G. Controlled prospective fifteen year follow-up of hyperactives as adults: non-medical drug and alcohol use and anti-social behaviour. Can J Psychiatry 1986;31:557-567
70. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985;142:1259-1264
71. Cocores JA, Davies RK, Mueller PS, et al. Cocaine abuse and adult attention deficit disorder. J Clin Psychiatry 1987;48:376-377
72. Levin FR, Evans SM, Yuan H, et al. Methylphenidate treatment of cocaine-abusing adults with ADHD. In: New Research Program and Abstracts of the 149th Annual Meeting of the American Psychiatric Association; May 7, 1996; New York, N.Y. Abstract NR273:141
73. Willner P. Dopamine and depression: a review of recent evidence, II: theoretical approaches. Brain Res 1983;287:225-236
74. Dackis CA, Gold MS. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev 1985;9:469-477
75. Milberger S, Biederman J, Faraone SV, et al. Further evidence of an association between attention-deficit/hyperactivity disorder and cigarette smoking: findings from a high risk sample of siblings. Am J Addict 1997; 6:205-217
76. Milberger S, Biederman J, Faraone SV, et al. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997;36:37-44
77. Kiba H, Jayaraman A. Nicotine induced c-fos expression in the striatum is mediated mostly by dopamine D1 receptor and is dependent on NMDA stimulation. Brain Res Mol Brain Res 1994;23:1-13
78. Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996;379:733-736
79. Fergusson DM, Lynskey MT, Horwood LJ. Comorbidity between depressive disorders and nicotine dependence in a cohort of 16-year-olds. Arch Gen Psychiatry 1996;53:1043-1047
80. Covey LS, Glassman AH, Stetner F. Major depression following smoking cessation. Am J Psychiatry 1997;154:263-265
81. Conners CK, Levin ED, Sparrow E, et al. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull 1996;32:67-73
82. Levin ED, Conners CK, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 1996; 123:55-63
83. Salin-Pascual RJ, de la Fuente JR, Galicia-Polo L, et al. Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacology (Berl) 1995;121:476-479
84. Gadow K, Sverd J, Sprafkin J, et al. Efficacy of methylphenidate for ADHD in children with tic disorder. Arch Gen Psychiatry 1995:444-455
85. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35:1314-1321
86. Spencer T, Biederman J, Steingard R, et al. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1993;32:211-214
87. Mattes J. Propranolol for adults with temper outbursts and residual attention deficit disorder. J Clin Psychopharmacol 1986;6:299-302
88. Bhandary AN, Gregory RJ, Carmen L, et al. Combination pharmacotherapy in ADHD. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 22, 1995; Miami Fla. Abstract NR157:96
89. Ratey JJ, Greenburg MS, Lindem KJ. Combination of treatments for attention deficit hyperactivity disorder in adults. J Nerv Ment Dis 1991;179: 699-701
90. Stovner AM, Wyller TB, Skulberg A, et al. Treatment of hyperactivity and attention deficit with amphetamine: experience with five adult prisoners (Norwegian). Tidsskr Nor Laegeforen 1996;116:2002-2005
91. Volovka J. Genetic and neurochemical correlates of violence. Psychiatr Ann 1997;27:679-682